Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Bioline RX Ltd Sponsored ADR (DE:YP2A)
FRANKFURT:YP2A
RESEARCH TOOLSreports
Bioline RX Ltd Sponsored ADR (YP2A) Stock Price & Analysis
0 Followers
YP2A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.54 - €2.38
Previous Close€0.59
Volume0.00
Average Volume (3M)N/A
Market Cap
€49.91M
Enterprise Value€20.34M
Total Cash (Recent Filing)$42.99M
Total Debt (Recent Filing)$11.59M
Price to Earnings (P/E)-0.7
Beta1.22
Next Earnings
May 22, 2024EPS Estimate
-€0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.88
Shares Outstanding72,439,278
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-27.60
Price to Sales (P/S)8.38
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit18.35
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
€19.69Price Target Upside3236.88% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Bioline RX Ltd Sponsored ADR News
PremiumCompany Announcements
BioLineRx Reveals Cost-Saving Stem Cell Mobilization Data
PremiumCompany Announcements
BioLineRx Enhances Multiple Myeloma Treatment
PremiumCompany Announcements
BiolineRx Ltd. Completes Significant Securities Offering
PremiumCompany Announcements
BioLineRx Announces Major Commercial MilestonesOptions Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
<0.01% Other Institutional Investors
99.95% Public Companies and
Individual Investors
YP2A FAQ
What was Bioline RX Ltd Sponsored ADR’s price range in the past 12 months?
Bioline RX Ltd Sponsored ADR lowest stock price was €0.54 and its highest was €2.38 in the past 12 months.
What is Bioline RX Ltd Sponsored ADR’s market cap?
Currently, no data Available
When is Bioline RX Ltd Sponsored ADR’s upcoming earnings report date?
Bioline RX Ltd Sponsored ADR’s upcoming earnings report date is May 22, 2024 which is in 14 days.
How were Bioline RX Ltd Sponsored ADR’s earnings last quarter?
Bioline RX Ltd Sponsored ADR released its earnings results on Mar 26, 2024. The company reported -€0.179 earnings per share for the quarter, beating the consensus estimate of -€0.207 by €0.028.
Is Bioline RX Ltd Sponsored ADR overvalued?
According to Wall Street analysts Bioline RX Ltd Sponsored ADR’s price is currently Undervalued.
Does Bioline RX Ltd Sponsored ADR pay dividends?
Bioline RX Ltd Sponsored ADR does not currently pay dividends.
What is Bioline RX Ltd Sponsored ADR’s EPS estimate?
Bioline RX Ltd Sponsored ADR’s EPS estimate is -€0.27.
How many shares outstanding does Bioline RX Ltd Sponsored ADR have?
Bioline RX Ltd Sponsored ADR has 79,939,280 shares outstanding.
What happened to Bioline RX Ltd Sponsored ADR’s price movement after its last earnings report?
Bioline RX Ltd Sponsored ADR reported an EPS of -€0.179 in its last earnings report, beating expectations of -€0.207. Following the earnings report the stock price went down -5.691%.
Which hedge fund is a major shareholder of Bioline RX Ltd Sponsored ADR?
Among the largest hedge funds holding Bioline RX Ltd Sponsored ADR’s share is ARK Investment Management LLC. It holds Bioline RX Ltd Sponsored ADR’s shares valued at N/A.
---
Bioline RX Ltd Sponsored ADR Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€19.69 (3236.88% Upside)
€19.69 (3236.88% Upside)
Blogger Sentiment
Bullish
DE:YP2A Sentiment 100%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-43.02%
12-Months-Change
Fundamentals
Return on Equity
-189.23%
Trailing 12-Months
Asset Growth
-16.31%
Trailing 12-Months
Company Description
Bioline RX Ltd Sponsored ADR
BioLineRx Ltd. is a clinical-stage biopharmaceutical company, which includes indentifying, in-licensing, and developing therapeutic candidates. Its in-licenses novel compounds, primarily from academic institutions and biotech companies based in Israel, and develops them through pre-clinical and clinical stages, and then partners with pharmaceutical companies clinical development and commercialization. The company was founded in April 2003 and is headquartered in Modi'in, Israel.
---
YP2A Stock 12 Month Forecast
Average Price Target
€19.69
▲(3236.88% Upside)
Technical Analysis
Best Analysts Covering YP2A
1 Year
1 Year Success Rate
8/26 ratings generated profit
1 Year Average Return
-17.06%
reiterated a buy rating 12 months ago
Copying Mark Breidenbach's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -17.06% per trade.
---